Corvus Pharmaceuticals (CRVS) Q4 2024 earnings summary

Executive summary

• R&D expenses increased in Q4 2024 to $6M, up from $4M in Q4 2023, mainly due to higher soquelitinib clinical trial costs.

• Net loss for Q4 2024 was $12.1M, including non-cash losses related to Angel Pharmaceuticals and warrant liability.

• Cash, cash equivalents, and marketable securities totaled $52M as of December 31, 2024, providing runway into Q1 2026.

• Early warrant exercises in Q4 2024 brought in $18.6M; full exercise could yield $41M more.

• Advanced soquelitinib, a selective ITK inhibitor, in multiple indications including atopic dermatitis, PTCL, and ALPS, with key clinical milestones achieved and further data readouts expected in 2025.

Financial highlights

• Full year 2024 R&D expenses were $19.4M, up from $16.5M in 2023, driven by soquelitinib development.

• Full year net loss was $63.3M, including $3.2M non-cash loss from Angel and $33.4M from warrant liability changes.

• Stock compensation expense for 2024 was $3M, up from $2.1M in 2023.

• Completed a registered direct offering in 2024, raising $30.3M.

• Cash, cash equivalents, and marketable securities totaled $52M as of December 31, 2024, up from $27.1M at year-end 2023.

Outlook and guidance

• Cash runway expected into Q1 2026, supporting execution of key milestones.

• Additional Phase 1 atopic dermatitis data (Cohorts 1–3) to be presented in May 2025; full phase 1 data in Q3; initiation of phase 2 trials in solid tumors and atopic dermatitis in late 2025.

• Interim data from the phase 3 PTCL trial anticipated in late 2026.

• Ongoing enrollment in Phase 3 PTCL and Phase 2 ALPS trials; continued focus on demonstrating soquelitinib's value across cancer and immune diseases.